RecruitingNCT05438836

Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

Sponsor

Herlev Hospital

Enrollment

205 participants

Start Date

Jan 1, 2022

Study Type

OBSERVATIONAL

Conditions

Anal Carcinoma Anal Cancer Anal Squamous Cell Carcinoma

Summary

A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether online adaptive radiotherapy — a cutting-edge form of radiation that adjusts the treatment plan in real time based on daily scans — improves outcomes and reduces side effects for people with anal cancer receiving curative (intent-to-cure) radiotherapy. **You may be eligible if:** - You have been diagnosed with anal cancer confirmed by biopsy - You are receiving radiotherapy with the goal of curing your cancer - You are able to provide written and oral consent **You may NOT be eligible if:** - You have had another type of cancer in the past 5 years (with the exception of basal cell skin cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.